Abstract
This review focuses on the therapeutic effects and mechanisms of action of NAP (davunetide), an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP) which was discovered in the laboratory of Prof. Illana Gozes. The effects of NAP and its related peptides in models of neurodegenerative diseases and other neurological disorders will be described here in details. Possible mechanisms of NAP actions include anti-inflammatory effect, antioxidant activity, inhibition of protein aggregation and interaction with microtubules. In line with the fact that all of these features are characteristic to most neurological/neurodegenerative disorders, NAP was found to have beneficial effects on the behavioral manifestations associated with these disorders.
Keywords: Activity-dependent neuroprotective protein (ADNP), Alzheimer's disease, Davunetide, NAP, neurodegenerative diseases, neurological disorders.
Current Medicinal Chemistry
Title:Davunetide: Peptide Therapeutic in Neurological Disorders
Volume: 21 Issue: 23
Author(s): Iddo Magen and Illana Gozes
Affiliation:
Keywords: Activity-dependent neuroprotective protein (ADNP), Alzheimer's disease, Davunetide, NAP, neurodegenerative diseases, neurological disorders.
Abstract: This review focuses on the therapeutic effects and mechanisms of action of NAP (davunetide), an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP) which was discovered in the laboratory of Prof. Illana Gozes. The effects of NAP and its related peptides in models of neurodegenerative diseases and other neurological disorders will be described here in details. Possible mechanisms of NAP actions include anti-inflammatory effect, antioxidant activity, inhibition of protein aggregation and interaction with microtubules. In line with the fact that all of these features are characteristic to most neurological/neurodegenerative disorders, NAP was found to have beneficial effects on the behavioral manifestations associated with these disorders.
Export Options
About this article
Cite this article as:
Magen Iddo and Gozes Illana, Davunetide: Peptide Therapeutic in Neurological Disorders, Current Medicinal Chemistry 2014; 21 (23) . https://dx.doi.org/10.2174/0929867321666140217124945
DOI https://dx.doi.org/10.2174/0929867321666140217124945 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Muscle Atrophy Classification: The Need for a Pathway-Driven Approach
Current Pharmaceutical Design Recent Patents Relating to siRNAs and Therapeutic Strategies for Genetic Diseases
Recent Patents on DNA & Gene Sequences Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy
Current Alzheimer Research Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Identification of Inflammatory, Metabolic, and Cell Survival Pathways Contributing to Cerebral Small Vessel Disease by Postmortem Gene Expression Microarray
Current Neurovascular Research Brain Oxidative Stress - Analytical Chemistry and Thermodynamics of Glutathione and NADPH
Current Topics in Medicinal Chemistry The 18-kDa Translocator Protein as a CNS Drug Target: Finding Our Way Through the Neuroinflammation Fog
CNS & Neurological Disorders - Drug Targets Zinc Homeostasis-regulating Proteins: New Drug Targets for Triggering Cell Fate
Current Drug Targets Creatine and the Liver: Metabolism and Possible Interactions
Mini-Reviews in Medicinal Chemistry Protective Substances Against Zinc-Induced Neuronal Death after Ischemia:Carnosine as a Target for Drug of Vascular Type of Dementia
Recent Patents on CNS Drug Discovery (Discontinued) Kainate Receptors and Pain: From Dorsal Root Ganglion to the Anterior Cingulate Cortex
Current Pharmaceutical Design Editorial: Neurodegenerative Disorders: Synthesis, Drug Delivery Strategies and Biological Evaluation of New Therapeutic Agents
Central Nervous System Agents in Medicinal Chemistry Derivatives of 6-Nitrobenzimidazole Inhibit Fructose-Mediated Protein Glycation and Intracellular Reactive Oxygen Species Production
Medicinal Chemistry Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Unique Medicinal Properties of Withania somnifera: Phytochemical Constituents and Protein Component
Current Pharmaceutical Design Patenting Activities Related to Biomedical Applications of Fullerenes
Recent Patents on Nanomedicine Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design The MT2 Melatonin Receptor Subtype is Present in Human Retina and Decreases in Alzheimers Disease
Current Alzheimer Research Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)